The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study

Tomotaka Saito; Kenji Hirano; Hiroyuki Isayama; Yousuke Nakai; Kei Saito; Gyotane Umefune; Dai Akiyama; Takeo Watanabe; Kaoru Takagi; Tsuyoshi Hamada; Naminatsu Takahara; Rie Uchino; Suguru Mizuno; Hirofumi Kogure; Saburo Matsubara; Natsuyo Yamamoto; Minoru Tada; Kazuhiko Koike

doi:10.1097/MPA.0000000000000767

The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study

Tomotaka Saito, Kenji Hirano, Hiroyuki Isayama, Yousuke Nakai, Kei Saito, Gyotane Umefune, Dai Akiyama, Takeo Watanabe, Kaoru Takagi, Tsuyoshi Hamada, Naminatsu Takahara, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Minoru Tada, Kazuhiko Koike

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

Objectives: Although patients with pancreatic cancer (PC) are prone to exocrine pancreatic insufficiency, there are little evidence about pancreatic enzyme replacement therapy (PERT) in patients with PC, especially those receiving chemotherapy. Methods: This is a prospective consecutive observational study of PERT in patientswith unresectable PC.We prospectively enrolled patients receiving chemotherapy for unresectable PC from April 2012 to February 2014 and prescribed oral pancrelipase of 48,000 lipase units permeal (pancrelipase group). N-benzoyl-tryrosyl para-aminobenzoic acid test was performed at baseline. Patients receiving chemotherapy before April 2012 were retrospectively studied as a historical cohort. Data on the nutritional markers at baseline and 16 weeks were extracted, and serial changes, defined as the ratio of markers at 16 weeks/baseline, were compared between 2 groups. Results: A total of 91 patients (46 in the pancrelipase group and 45 in the historical cohort) were analyzed. N-benzoyl-tryrosyl para-aminobenzoic acid test was low in 94% of the pancrelipase group. Serial change in the pancrelipase group versus historical cohort was 1.01 versus 0.95 in body mass index (P < 0.001) and 1.03 versus 0.97 in serumalbumin (P = 0.131). Conclusions: The rate of exocrine pancreatic insufficiency in unresectable PC was high, and PERT can potentially improve the nutritional status during chemotherapy.

Original language	English
Pages (from-to)	341-346
Number of pages	6
Journal	Pancreas
Volume	46
Issue number	3
DOIs	https://doi.org/10.1097/MPA.0000000000000767
Publication status	Published - 1 Mar 2017
Externally published	Yes

Keywords

Chemotherapy
Enzyme replacement therapy
Exocrine pancreatic
Insufficiency
Nutritional status
Pancreatic cancer
Pancrelipase

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MPA.0000000000000767

Cite this

Saito, T., Hirano, K., Isayama, H., Nakai, Y., Saito, K., Umefune, G., Akiyama, D., Watanabe, T., Takagi, K., Hamada, T., Takahara, N., Uchino, R., Mizuno, S., Kogure, H., Matsubara, S., Yamamoto, N., Tada, M., & Koike, K. (2017). The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study. Pancreas, 46(3), 341-346. https://doi.org/10.1097/MPA.0000000000000767

@article{9d71bfcf835d432eb13e4d766a2f6645,

title = "The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study",

abstract = "Objectives: Although patients with pancreatic cancer (PC) are prone to exocrine pancreatic insufficiency, there are little evidence about pancreatic enzyme replacement therapy (PERT) in patients with PC, especially those receiving chemotherapy. Methods: This is a prospective consecutive observational study of PERT in patientswith unresectable PC.We prospectively enrolled patients receiving chemotherapy for unresectable PC from April 2012 to February 2014 and prescribed oral pancrelipase of 48,000 lipase units permeal (pancrelipase group). N-benzoyl-tryrosyl para-aminobenzoic acid test was performed at baseline. Patients receiving chemotherapy before April 2012 were retrospectively studied as a historical cohort. Data on the nutritional markers at baseline and 16 weeks were extracted, and serial changes, defined as the ratio of markers at 16 weeks/baseline, were compared between 2 groups. Results: A total of 91 patients (46 in the pancrelipase group and 45 in the historical cohort) were analyzed. N-benzoyl-tryrosyl para-aminobenzoic acid test was low in 94% of the pancrelipase group. Serial change in the pancrelipase group versus historical cohort was 1.01 versus 0.95 in body mass index (P < 0.001) and 1.03 versus 0.97 in serumalbumin (P = 0.131). Conclusions: The rate of exocrine pancreatic insufficiency in unresectable PC was high, and PERT can potentially improve the nutritional status during chemotherapy.",

keywords = "Chemotherapy, Enzyme replacement therapy, Exocrine pancreatic, Insufficiency, Nutritional status, Pancreatic cancer, Pancrelipase",

author = "Tomotaka Saito and Kenji Hirano and Hiroyuki Isayama and Yousuke Nakai and Kei Saito and Gyotane Umefune and Dai Akiyama and Takeo Watanabe and Kaoru Takagi and Tsuyoshi Hamada and Naminatsu Takahara and Rie Uchino and Suguru Mizuno and Hirofumi Kogure and Saburo Matsubara and Natsuyo Yamamoto and Minoru Tada and Kazuhiko Koike",

year = "2017",

month = mar,

day = "1",

doi = "10.1097/MPA.0000000000000767",

language = "English",

volume = "46",

pages = "341--346",

journal = "Pancreas",

issn = "0885-3177",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

Saito, T, Hirano, K, Isayama, H, Nakai, Y, Saito, K, Umefune, G, Akiyama, D, Watanabe, T, Takagi, K, Hamada, T, Takahara, N, Uchino, R, Mizuno, S, Kogure, H, Matsubara, S, Yamamoto, N, Tada, M & Koike, K 2017, 'The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study', Pancreas, vol. 46, no. 3, pp. 341-346. https://doi.org/10.1097/MPA.0000000000000767

TY - JOUR

T1 - The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer

T2 - A prospective cohort study

AU - Saito, Tomotaka

AU - Hirano, Kenji

AU - Isayama, Hiroyuki

AU - Nakai, Yousuke

AU - Saito, Kei

AU - Umefune, Gyotane

AU - Akiyama, Dai

AU - Watanabe, Takeo

AU - Takagi, Kaoru

AU - Hamada, Tsuyoshi

AU - Takahara, Naminatsu

AU - Uchino, Rie

AU - Mizuno, Suguru

AU - Kogure, Hirofumi

AU - Matsubara, Saburo

AU - Yamamoto, Natsuyo

AU - Tada, Minoru

AU - Koike, Kazuhiko

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives: Although patients with pancreatic cancer (PC) are prone to exocrine pancreatic insufficiency, there are little evidence about pancreatic enzyme replacement therapy (PERT) in patients with PC, especially those receiving chemotherapy. Methods: This is a prospective consecutive observational study of PERT in patientswith unresectable PC.We prospectively enrolled patients receiving chemotherapy for unresectable PC from April 2012 to February 2014 and prescribed oral pancrelipase of 48,000 lipase units permeal (pancrelipase group). N-benzoyl-tryrosyl para-aminobenzoic acid test was performed at baseline. Patients receiving chemotherapy before April 2012 were retrospectively studied as a historical cohort. Data on the nutritional markers at baseline and 16 weeks were extracted, and serial changes, defined as the ratio of markers at 16 weeks/baseline, were compared between 2 groups. Results: A total of 91 patients (46 in the pancrelipase group and 45 in the historical cohort) were analyzed. N-benzoyl-tryrosyl para-aminobenzoic acid test was low in 94% of the pancrelipase group. Serial change in the pancrelipase group versus historical cohort was 1.01 versus 0.95 in body mass index (P < 0.001) and 1.03 versus 0.97 in serumalbumin (P = 0.131). Conclusions: The rate of exocrine pancreatic insufficiency in unresectable PC was high, and PERT can potentially improve the nutritional status during chemotherapy.

AB - Objectives: Although patients with pancreatic cancer (PC) are prone to exocrine pancreatic insufficiency, there are little evidence about pancreatic enzyme replacement therapy (PERT) in patients with PC, especially those receiving chemotherapy. Methods: This is a prospective consecutive observational study of PERT in patientswith unresectable PC.We prospectively enrolled patients receiving chemotherapy for unresectable PC from April 2012 to February 2014 and prescribed oral pancrelipase of 48,000 lipase units permeal (pancrelipase group). N-benzoyl-tryrosyl para-aminobenzoic acid test was performed at baseline. Patients receiving chemotherapy before April 2012 were retrospectively studied as a historical cohort. Data on the nutritional markers at baseline and 16 weeks were extracted, and serial changes, defined as the ratio of markers at 16 weeks/baseline, were compared between 2 groups. Results: A total of 91 patients (46 in the pancrelipase group and 45 in the historical cohort) were analyzed. N-benzoyl-tryrosyl para-aminobenzoic acid test was low in 94% of the pancrelipase group. Serial change in the pancrelipase group versus historical cohort was 1.01 versus 0.95 in body mass index (P < 0.001) and 1.03 versus 0.97 in serumalbumin (P = 0.131). Conclusions: The rate of exocrine pancreatic insufficiency in unresectable PC was high, and PERT can potentially improve the nutritional status during chemotherapy.

KW - Chemotherapy

KW - Enzyme replacement therapy

KW - Exocrine pancreatic

KW - Insufficiency

KW - Nutritional status

KW - Pancreatic cancer

KW - Pancrelipase

UR - http://www.scopus.com/inward/record.url?scp=85009781719&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000767

DO - 10.1097/MPA.0000000000000767

M3 - Article

C2 - 28099252

AN - SCOPUS:85009781719

SN - 0885-3177

VL - 46

SP - 341

EP - 346

JO - Pancreas

JF - Pancreas

IS - 3

ER -

The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this